Results 141 to 150 of about 6,882 (175)
Eltrombopag Before Procedures in Patients With Cirrhosis and Thrombocytopenia [PDF]
New England Journal of Medicine, 2012 Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are ...
Chen Pei-jer +2 more
exaly +4 more sources
Eltrombopag for Management of Chronic Immune Thrombocytopenia (RAISE): A 6-Month, Randomised, Phase 3 Study [PDF]
Lancet, The, 2011 Background: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period ...
Gregory Cheng +2 more
exaly +2 more sources
Eltrombopag for Thrombocytopenia in Patients With Cirrhosis Associated With Hepatitis C [PDF]
New England Journal of Medicine, 2007 Background Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with ...
Mitchell L Shiffman +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2009
Eltrombopag, an orally administered, small-molecule non-peptide thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells.
Karly P, Garnock-Jones, Susan J, Keam
openaire +2 more sources
Eltrombopag, an orally administered, small-molecule non-peptide thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells.
Karly P, Garnock-Jones, Susan J, Keam
openaire +2 more sources
2010
The current concepts and the management of ITP have significantly changed in the past decade. Decreased use of cytotoxic therapy and the introduction of new selective modalities of drug such as TPO-r mimetics are the landmarks of this change. Discovered in the middle of last decade, followed by experiments in mice and then approved in humans ...
James B, Bussel, Mariana P, Pinheiro
openaire +2 more sources
The current concepts and the management of ITP have significantly changed in the past decade. Decreased use of cytotoxic therapy and the introduction of new selective modalities of drug such as TPO-r mimetics are the landmarks of this change. Discovered in the middle of last decade, followed by experiments in mice and then approved in humans ...
James B, Bussel, Mariana P, Pinheiro
openaire +2 more sources